IS8136A - N-pýrrólidín-3-ýl-amíð afleiður sem serótónín og noradrenalín endurupptöku hindrar - Google Patents

N-pýrrólidín-3-ýl-amíð afleiður sem serótónín og noradrenalín endurupptöku hindrar

Info

Publication number
IS8136A
IS8136A IS8136A IS8136A IS8136A IS 8136 A IS8136 A IS 8136A IS 8136 A IS8136 A IS 8136A IS 8136 A IS8136 A IS 8136A IS 8136 A IS8136 A IS 8136A
Authority
IS
Iceland
Prior art keywords
pyrrolidin
amide derivatives
norepinephrine reuptake
inhibit serotonin
serotonin
Prior art date
Application number
IS8136A
Other languages
English (en)
Inventor
Vincent Fish Paul
Jonathan Fray Michael
Jane Lovering Deborah
Stobie Alan
Wakenhut Florian
Alistair Whitlock Gavin
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0314048.0A external-priority patent/GB0314048D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of IS8136A publication Critical patent/IS8136A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS8136A 2003-06-17 2005-11-21 N-pýrrólidín-3-ýl-amíð afleiður sem serótónín og noradrenalín endurupptöku hindrar IS8136A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0314048.0A GB0314048D0 (en) 2003-06-17 2003-06-17 Novel compounds
US49312603P 2003-08-06 2003-08-06
PCT/IB2004/001943 WO2004110995A1 (en) 2003-06-17 2004-06-07 N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors

Publications (1)

Publication Number Publication Date
IS8136A true IS8136A (is) 2005-11-21

Family

ID=33554153

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8136A IS8136A (is) 2003-06-17 2005-11-21 N-pýrrólidín-3-ýl-amíð afleiður sem serótónín og noradrenalín endurupptöku hindrar

Country Status (31)

Country Link
US (2) US7378436B2 (is)
EP (1) EP1638933B1 (is)
JP (1) JP4137159B2 (is)
KR (1) KR100803796B1 (is)
AP (1) AP2005003467A0 (is)
AR (1) AR044715A1 (is)
AT (1) ATE398107T1 (is)
AU (1) AU2004247487B2 (is)
BR (1) BRPI0411594A (is)
CA (1) CA2530159C (is)
CY (1) CY1110434T1 (is)
DE (1) DE602004014372D1 (is)
DK (1) DK1638933T3 (is)
EA (1) EA009881B1 (is)
EC (1) ECSP056232A (is)
ES (1) ES2305776T3 (is)
HR (2) HRP20080339T3 (is)
IL (1) IL172063A0 (is)
IS (1) IS8136A (is)
MA (1) MA27885A1 (is)
MX (1) MXPA05013960A (is)
NL (1) NL1026438C2 (is)
NZ (1) NZ544046A (is)
PA (1) PA8605301A1 (is)
PE (1) PE20050631A1 (is)
PL (1) PL1638933T3 (is)
PT (1) PT1638933E (is)
SI (1) SI1638933T1 (is)
TW (1) TW200505852A (is)
UY (1) UY28360A1 (is)
WO (1) WO2004110995A1 (is)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006384B1 (ru) * 2000-07-31 2005-12-29 Нюкомед Данмарк А/С Композиция фентанила для интраназального введения
MXPA05013960A (es) * 2003-06-17 2006-02-24 Pfizer Nuevos compuestos.
CN101094846A (zh) 2004-10-18 2007-12-26 伊莱利利公司 用作mglur3受体拮抗剂的1－(杂)芳基－3－氨基－吡咯烷衍生物
GB0425766D0 (en) * 2004-11-23 2004-12-22 Pfizer Ltd Novel compounds
US7122683B2 (en) 2004-11-23 2006-10-17 Pfizer Inc. Amides useful as monoamine re-uptake inhibitors
WO2006064336A2 (en) * 2004-12-14 2006-06-22 Pfizer Limited N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors
WO2006064332A1 (en) * 2004-12-14 2006-06-22 Pfizer Limited N-pyrrolidin-3yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors
TWI449692B (zh) 2005-05-13 2014-08-21 Otsuka Pharma Co Ltd 吡咯烷化合物（三）
ES2330788T3 (es) 2005-06-02 2009-12-15 F. Hoffmann-La Roche Ag Derivados de piperidin-4-il-amida y su uso como antagonistas del subtipo 5 del receptor sst.
WO2007135530A2 (en) * 2006-05-22 2007-11-29 Pfizer Limited Pharmaceutically & veterinarily suitable salt
US20080014152A1 (en) * 2006-07-13 2008-01-17 Di Mauro Thomas M Intranasal delivery of clenbuterol across the cribriform plate and into the brain
JP5219465B2 (ja) * 2006-11-10 2013-06-26 大塚製薬株式会社 医薬
EP2119702A4 (en) * 2007-01-31 2010-12-08 Dainippon Sumitomo Pharma Co amide derivative
JP2010189275A (ja) * 2007-06-14 2010-09-02 Dainippon Sumitomo Pharma Co Ltd ナフタレン誘導体
US8263652B2 (en) 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
JP5484069B2 (ja) * 2007-12-19 2014-05-07 大日本住友製薬株式会社 二環性へテロ環誘導体
ES2434250T3 (es) 2008-07-24 2013-12-16 Theravance, Inc. Compuestos de 3-(fenoxifenilmetil)pirrolidina
NZ592543A (en) 2008-11-14 2013-02-22 Theravance Inc 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
JP2012524098A (ja) * 2009-04-15 2012-10-11 セラヴァンス， インコーポレーテッド ３−（フェノキシピロリジン−３−イル−メチル）ヘテロアリール、３−（フェニルピロリジン−３−イルメトキシ）ヘテロアリールおよび３−（ヘテロアリールピロリジン−３−イルメトキシ）ヘテロアリール化合物
KR20120109292A (ko) 2009-06-24 2012-10-08 다이닛본 스미토모 세이야꾸 가부시끼가이샤 Ｎ-치환-시클릭 아미노 유도체
US7994209B2 (en) 2009-07-13 2011-08-09 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
JP5714580B2 (ja) 2009-07-21 2015-05-07 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ３−フェノキシメチルピロリジン化合物
US8778949B2 (en) * 2010-01-11 2014-07-15 Theravance Biopharma R&D Ip, Llc 1-(2-phenoxymethylphenyl)piperazine compounds
JP5769348B2 (ja) * 2010-03-22 2015-08-26 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー １−（２−フェノキシメチルヘテロアリール）ピペリジン化合物および１−（２−フェノキシメチルヘテロアリール）ピペラジン化合物
JP5873877B2 (ja) 2010-10-11 2016-03-01 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー セロトニン再取込みインヒビター
WO2012075239A1 (en) 2010-12-03 2012-06-07 Theravance, Inc. Serotonin reuptake inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE138773C (is)
US3963745A (en) * 1972-04-03 1976-06-15 A. H. Robins Company, Incorporated Method for controlling emesis with N-(1-substituted-3-pyrrolidinyl)benzamides and thiobenzamides
US4002757A (en) * 1974-12-26 1977-01-11 A. H. Robins Company, Incorporated N-(1-substituted-3-pyrrolidinyl)-4-quinolinecarboxamides
US4020072A (en) 1976-05-04 1977-04-26 E. R. Squibb & Sons, Inc. 5-Aminomethyl-1H-pyrazolo[3,4-b]pyridines
GB1574419A (en) * 1977-11-11 1980-09-03 Anphar Sa Piperidine compounds
CH628885A5 (en) * 1978-01-01 1982-03-31 Anphar Sa Piperidine derivative
US5130312A (en) * 1987-07-17 1992-07-14 Janssen Pharmaceutica N.V. Substituted N-(3-hydroxy-4-piperidinyl)benzamides
FR2642069B1 (fr) 1989-01-20 1991-04-12 Rhone Poulenc Sante Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent
JP2000500502A (ja) 1995-11-22 2000-01-18 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
AU4167099A (en) 1998-06-19 2000-01-05 Nissan Chemical Industries Ltd. Heterocyclic compounds as hypoglycemic agents
US6670299B1 (en) * 1999-07-03 2003-12-30 Northwestern University Cyclopentadienyl-containing low-valent early transition metal olefin polymerization catalysts
FR2802206B1 (fr) 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
EP2133078A1 (en) 2000-03-03 2009-12-16 Eisai R&D Management Co., Ltd. Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments
RU2002126554A (ru) * 2000-03-06 2004-03-20 Акадиа Фармасьютикалз, Инк. (Us) Азациклические соединения для применения при лечении опосредованных серотонином заболеваний
US7109199B2 (en) 2000-09-22 2006-09-19 Smithkline Beecham Corporation Pyrazolopyridines and pyrazolopyridazines as antidiabetics
US20040102431A1 (en) 2000-09-25 2004-05-27 Christoph Boss Substituted amino-aza-cycloalkanes useful against malaria
ATE479655T1 (de) 2001-09-14 2010-09-15 High Point Pharmaceuticals Llc Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
US20050228017A1 (en) 2001-10-31 2005-10-13 Morphochem Aktiengesellschaft Fur Kombinatorische Chemie Novel anticancer compounds
GB0128287D0 (en) 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
CN100509804C (zh) * 2002-06-24 2009-07-08 阿卡蒂亚药品公司 N-取代哌啶衍生物作为血清素受体试剂
WO2004009549A2 (en) 2002-07-18 2004-01-29 Actelion Pharmaceuticals Ltd Piperidines useful for the treatment of central nervous system disorders
WO2004022536A1 (en) 2002-09-04 2004-03-18 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
KR101061352B1 (ko) 2002-12-20 2011-08-31 케모센트릭스 인간 종양-발현된 ｃｃｘｃｋｒ2의 저해물질
MXPA05013960A (es) * 2003-06-17 2006-02-24 Pfizer Nuevos compuestos.

Also Published As

Publication number Publication date
TW200505852A (en) 2005-02-16
NZ544046A (en) 2009-08-28
NL1026438A1 (nl) 2004-12-20
UY28360A1 (es) 2005-01-31
CY1110434T1 (el) 2015-04-29
PL1638933T3 (pl) 2008-10-31
IL172063A0 (en) 2009-02-11
PA8605301A1 (es) 2005-02-04
DE602004014372D1 (de) 2008-07-24
AR044715A1 (es) 2005-09-21
PE20050631A1 (es) 2005-09-14
BRPI0411594A (pt) 2006-08-29
AU2004247487A1 (en) 2004-12-23
EA200501730A1 (ru) 2006-08-25
CA2530159A1 (en) 2004-12-23
EP1638933B1 (en) 2008-06-11
PT1638933E (pt) 2008-07-22
DK1638933T3 (da) 2008-07-28
US20050137229A1 (en) 2005-06-23
NL1026438C2 (nl) 2005-09-20
CA2530159C (en) 2010-02-02
US7378436B2 (en) 2008-05-27
KR100803796B1 (ko) 2008-02-14
JP2006527758A (ja) 2006-12-07
MXPA05013960A (es) 2006-02-24
MA27885A1 (fr) 2006-05-02
WO2004110995A8 (en) 2005-04-21
JP4137159B2 (ja) 2008-08-20
AU2004247487B2 (en) 2010-05-20
US20080306123A1 (en) 2008-12-11
HRP20050993A2 (en) 2006-03-31
ATE398107T1 (de) 2008-07-15
WO2004110995A1 (en) 2004-12-23
ES2305776T3 (es) 2008-11-01
HRP20080339T3 (en) 2008-08-31
SI1638933T1 (sl) 2008-10-31
ECSP056232A (es) 2006-04-19
EA009881B1 (ru) 2008-04-28
AP2005003467A0 (en) 2006-12-31
EP1638933A1 (en) 2006-03-29
KR20060036927A (ko) 2006-05-02

Similar Documents

Publication Publication Date Title
IS8136A (is) N-pýrrólidín-3-ýl-amíð afleiður sem serótónín og noradrenalín endurupptöku hindrar
IS2732B (is) Fenýl-píperidín afleiður sem serótónín endurupptökuhindrar
NO2017017I1 (no) umeklinidium og vilanterol
EE200300478A (et) Tsüklopropüülindooli derivaadid kui selektiivsed serotoniini tagasihaarde inhibiitorid
DK1765327T3 (da) Forbindelser, sammensætninger og fremgangsmåder
IS2693B (is) Fenoxýediksýruafleiður
NL1030486A1 (nl) Dibenzylamineverbindingen en derivaten.
ZA200800408B (en) Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof
IS6704A (is) Fenoxýbensýlamínafleiður sem valvísir serótónín endurupptöku hindrar
NO20043124L (no) Aminoindanderivater som serotonin -og norepinefrin-opptaksinhibitorer
DK1643985T3 (da) Kombinationen af en serotonin-genoptagelseshæmmer og agomelatin
FI20031004A0 (fi) Uusi syötävä koostumus
NL1026989A1 (nl) Combinatie van serotonineheropnameremmers en norepinefrineheropnameremmers.
IS8326A (is) Blandan af serótónín endurupptöku hindra og loxapíni
TWI339658B (en) Morpholine derivatives as norepinephrine reuptake inhibitors
IS7996A (is) 4-(2-fenýlsúlfanýl-fenýl)-píperidín afleiður sem serótónín endurupptöku hindrar
IS7282A (is) Amínóindan afleiður sem serótónín og noradrenalínupptökuhindrar
GB0318706D0 (en) Selective serotonin reuptake inhibitors in the treatment of disease
EP1681284A4 (en) AROMATIC POLYAMINE DERIVATIVE
IS2551B (is) 2-(1H-indólýlsúlfanýl)-bensýl amín afleiður sem valvís serótónín endurupptöku hindri (SSRI)
ATA4192004A (de) Marinade
ZA200509132B (en) N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors
IS7866A (is) Nýjar píperidínafleiður og notkun þeirra sem mónóamín-taugaboðefna-endurupptökuhindrar
HK1115371A (en) Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof
ES1054509Y (es) Nueva raqueta para paddel